Research ArticleOriginal Article
Open Access

Prevalence of extended-spectrum β-lactamase and carbapenem-resistant Klebsiella pneumoniae in clinical samples

Amela Dedeić Ljubović, Ðana Granov, Erna Husić, Džemilja Gačanović, Jasmina Halković, Azra Čamdžić lab.ing, Šejla Kotorić Keser and Svjetlana Loga Zec
Saudi Medical Journal August 2023, 44 (8) 801-807; DOI: https://doi.org/10.15537/smj.2023.44.8.20230237

References

  1. 1.↵
    1. Russo TA,
    2. Marr CM.
    Hypervirulent Klebsiella pneumoniae. Clin Microbiol Rev 20195; 32: e00001–e00019.
    OpenUrlCrossRef
  2. 2.↵
    1. Davarcı İ,
    2. Şenbayrak S,
    3. Aksaray S,
    4. Koçoğlu M,
    5. Kuşkucu M,
    6. Samastı M.
    Molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae Isolates. Anatol Clin 2019; 24: 1–7.
    OpenUrl
  3. 3.↵
    1. Qiu Y,
    2. Lin D,
    3. Xu Y,
    4. Cheng Y,
    5. Wang F,
    6. Zhu Q, et al.
    Invasive Klebsiella pneumoniae Infections in community-settings and healthcare settings. Infect Drug Resist 2021; 14: 2647–2656.
    OpenUrlPubMed
  4. 4.↵
    European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe – Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2017. [Updated 2018; Accessed 2023 Feb 25]. Available from: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2017
  5. 5.↵
    1. Padmini N,
    2. Ajilda AAK,
    3. Sivakumar N,
    4. Selvakumar G.
    Extended spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae: critical tools for antibiotic resistance pattern. J Basic Microbiol 2017; 57: 460–470.
    OpenUrl
  6. 6.↵
    1. Doi Y,
    2. Paterson DL. Carbapenemase-producing Enterobacteriaceae
    . Semin Respir Crit Care Med 2015; 36: 74–84.
    OpenUrlCrossRefPubMed
  7. 7.↵
    The European Committee on Antimicrobial Susceptibility Testing. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance, version 2.0. [Updated 2017; Accessed 2023 April 12]. Available from: https://www.eucast.org/resistance_mechanisms
  8. 8.↵
    1. Granov D,
    2. Dedeić-Ljubović A,
    3. Salimović-Bešić I.
    Characterization of Carbapenemase-Producing Klebsiella pneumoniae in Clinical Center University of Sarajevo, Bosnia and Herzegovina. Microb Drug Resist 2020; 26: 1038–1045.
    OpenUrl
  9. 9.↵
    1. Bayraktar B,
    2. Pelit S,
    3. Bulut ME,
    4. Aktaş E.
    Trend in antibiotic resistance of extended-spectrum beta-lactamase-producing Escherichia Coli and Klebsiella Pneumoniae bloodstream infections. Sisli Etfal Hastan Tip Bul 2019; 53: 70–75.
    OpenUrl
  10. 10.↵
    1. Caneiras C,
    2. Lito L,
    3. Melo-Cristino J,
    4. Duarte A.
    Community- and hospital-acquired Klebsiella pneumoniae urinary tract infections in Portugal: Virulence and antibiotic resistance. Microorganisms 2019; 7: 138.
    OpenUrl
  11. 11.↵
    1. Balasubramanian B,
    2. Benit N,
    3. Agastian P,
    4. Almaary KS,
    5. Dawoud TM,
    6. Elbadawi YB,
    7. Mubarak A, et al.
    Carbapenemases producing Klebsiella pneumoniae from the pus of hospitalized patients: In-vitro antibiotic properties of Streptomyces against multidrug resistant infectious bacteria. J Infect Public Health 2021; 14: 892–897.
    OpenUrl
  12. 12.↵
    World Health Organization Regional Office for Europe/European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2022–2020 data. [Updated 2022; Accessed 2023 April 2]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Joint-WHO-ECDC-AMR-report-2022.pdf
  13. 13.↵
    1. Farhadi M,
    2. Ahanjan M,
    3. Goli HR,
    4. Haghshenas MR,
    5. Gholami M.
    High frequency of multidrug-resistant (MDR) Klebsiella pneumoniae harboring several β-lactamase and integron genes collected from several hospitals in the north of Iran. Ann Clin Microbiol Antimicrob 2021; 20: 70.
    OpenUrl
  14. 14.↵
    World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed. [Updated 2017; Accessed 2020 September 22]; Available from: https://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed
  15. 15.↵
    Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. [Updated 2013; Accessed 2023 March 25]. Available: http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf
  16. 16.↵
    1. Al Mously N,
    2. Al Arfaj O,
    3. Al Fadhil L,
    4. Mukaddam S.
    Antimicrobial susceptibility patterns of ESBL Escherichia coli isolated from the community and hospital-acquired urinary tract infections. J Health Specialties 2016; 4: 133.
    OpenUrl
  17. 17.↵
    1. Pathak J,
    2. Pokharel N.
    Multidrug-resistant and extended-spectrum β-lactamase (ESBL) isolates from different clinical specimens. Int J Sci and Res Pub 2015; 5: 1–5.
    OpenUrl
  18. 18.↵
    1. Dedeic-Ljubovic A.
    Sensitivity and resistance of bacteria on antimicrobial drugs in Clinical Center University of Sarajevo (2013-2016). Sarajevo: Institute of science, research, and development CCUS. 2017; 90 pages.
  19. 19.↵
    1. Karruli A,
    2. Boccia F,
    3. Gagliardi M,
    4. Patauner F,
    5. Ursi MP,
    6. Sommese P,et al
    . Multidrug-resistant infections and outcome of critically Ill patients with coronavirus disease 2019: A single center experience. Microb Drug Resist 2021; 27: 1167–1175.
    OpenUrl
  20. 20.↵
    1. Tiri B,
    2. Sensi E,
    3. Marsiliani V,
    4. Cantarini M,
    5. Priante, Vernelli C, et al.
    Antimicrobial stewardship program, COVID-19, and infection control: spread of carbapenem-resistant Klebsiella Pneumoniae colonization in ICU COVID-19 patients. What did not work? J Clin Med 2020; 9: 2744.
    OpenUrl
  21. 21.↵
    1. Gomez-Simmonds A,
    2. Annavajhala MK,
    3. McConville TH,
    4. Dietz DE,
    5. Shoucri SM,
    6. Laracy JC, et al.
    Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital. J Antimicrob Chemother 2021; 76: 380–384.
    OpenUrl
  22. 22.
    1. Shbaklo N,
    2. Corcione S,
    3. Vicentini C,
    4. Giordano S,
    5. Fiorentino D,
    6. Bianco G, et al.
    An observational study of MDR hospital-acquired infections and antibiotic use during COVID-19 pandemic: A call for antimicrobial stewardship programs. Antibiotics (Basel) 2022; 11: 695.
    OpenUrl
  23. 23.↵
    1. Cañada-García JE,
    2. Ramírez de Arellano E,
    3. Jiménez-Orellana M,
    4. Viedma E,
    5. Sánchez A,
    6. Alhambra A, et al.
    Carbapenemase-Producing Klebsiella pneumoniae in COVID-19 intensive care patients: identification of IncL-VIM-1 plasmid in previously non-predominant sequence types. Antibiotics (Basel) 2023; 12: 107.
    OpenUrl
  24. 24.↵
    1. Rawson TM,
    2. Moore LSP,
    3. Zhu N,
    4. Ranganathan N,
    5. Skolimowska K,
    6. Gilchrist M, et al.
    Bacterial and fungal coinfection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020; 71: 2459–2468.
    OpenUrlCrossRefPubMed
  25. 25.
    1. Mędrzycka-Dąbrowska W,
    2. Lange S,
    3. Zorena K,
    4. Dąbrowski S,
    5. Ozga D,
    6. Tomaszek L.
    Carbapenem-Resistant Klebsiella pneumoniae infections in ICU COVID-19 patients-a scoping review. J Clin Med 2021;10: 2067.
  26. 26.↵
    1. Chedid M,
    2. Waked R,
    3. Haddad E,
    4. Chetata N,
    5. Saliba G,
    6. Choucair J.
    Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy. J Infect Public Health 2021; 14: 570–576.
    OpenUrl
  27. 27.↵
    1. Bengoechea JA,
    2. Bamford CG.
    SARS-CoV-2, bacterial co-infections, and AMR: the deadly trio in COVID-19? EMBO Mol Med 2020; 12: e12560.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Paterson DL,
    2. Bonomo RA.
    Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005;18: 657–686.
    OpenUrl
  29. 29.↵
    1. Yan L,
    2. Sun J,
    3. Xu X,
    4. Huang S.
    Epidemiology and risk factors of rectal colonization of carbapenemase-producing Enterobacteriaceae among high-risk patients from ICU and HSCT wards in a university hospital. Antimicrob Resist Infect Control 2020; 9: 155.
    OpenUrl
  30. 30.↵
    1. Pisney LM,
    2. Barron MA,
    3. Kassner E,
    4. Havens D,
    5. Madinger NE.
    Carbapenem-resistant Enterobacteriaceae rectal screening during an outbreak of New Delhi metallo- β-lactamase-producing Klebsiella pneumoniae at an acute care hospital. Infect Control Hosp Epidemiol 2014; 35: 434–436.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Sarowska J,
    2. Choroszy-Krol I,
    3. Jama-Kmiecik A,
    4. Maczynska B,
    5. Cholewa S,
    6. Frej-Madrzak M.
    Occurrence and characteristics of carbapenem-resistant Klebsiella pneumoniae strains isolated from hospitalized patients in Poland—A single centre study. Pathogens 2022; 11: 859.
    OpenUrl
  32. 32.↵
    1. Del Bianco F,
    2. Morotti M,
    3. Zannoli S,
    4. Dirani G,
    5. Fantini M,
    6. Pedna MF, et al.
    Comparison of four commercial screening assays for the detection of blaKPC, blaNDM, blaIMP, blaVIM, and blaOXA48 in rectal secretion collected by swabs. Microorganisms 2019; 7: 704.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords